International Journal of Medical Informatics, Journal Year: 2024, Volume and Issue: 191, P. 105581 - 105581
Published: July 30, 2024
Language: Английский
Metabolites, Journal Year: 2021, Volume and Issue: 11(2), P. 73 - 73
Published: Jan. 27, 2021
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) identify placebo-controlled active-controlled RCTs using different GLP-1 RAs. We included eleven phase-2 (involving total 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide 3 dulaglutide 1 RCT) semaglutide specifically treat NAFLD NASH, detected by biopsy 2 RCTs) imaging techniques 9 RCTs). Compared placebo reference therapy, with RAs median 26 weeks was associated significant reductions in absolute percentage fat content on magnetic resonance-based (pooled weighted mean difference: -3.92%, 95% confidence intervals (CI) -6.27% -1.56%) serum enzyme levels, as well greater histological resolution NASH without worsening fibrosis random-effects odds ratio 4.06, CI 2.52-6.55; only). In conclusion, (mostly semaglutide) is promising option warrants further investigation.
Language: Английский
Citations
217
Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)
Published: March 23, 2022
Abstract Background We conducted a systematic review and meta-analysis of the cardiovascular, kidney, safety outcomes sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetic kidney disease (DKD). Methods searched electronic databases for major randomized placebo-controlled clinical trials published up to September 30, 2021 reporting on cardiovascular SGLT2i in DKD. DKD was defined as chronic individuals type diabetes. Random-effects models were used estimate pooled hazard ratios (HR) 95% confidence intervals (CI) including adverse events (MACE: myocardial infarction [MI], stroke, death), composite (a combination worsening function, end-stage disease, or death from renal causes), hospitalizations heart failure (HHF), deaths (mycotic infections, ketoacidosis [DKA], volume depletion, amputations, fractures, urinary tract infections [UTI], acute injury [AKI], hyperkalemia). Results A total 26,106 participants 8 large-scale included (median age: 65.2 years, 29.7–41.8% women, 53.2–93.2% White, median follow-up: 2.5 years). associated reduced risks MACE (HR 0.83, CI 0.75–0.93), 0.66, 0.58–0.75), HHF 0.62, 0.55–0.71), 0.84, 0.74–0.96), MI 0.78, 0.67–0.92), stroke 0.76, 0.59–0.97), all-cause 0.86, 0.77–0.96), no significant heterogeneity detected. Similar results observed estimated glomerular filtration rate (eGFR: < 60 mL/min/1.73m ). The relative (95% CI) 3.89 (1.42–10.62) 2.50 (1.32–4.72) mycotic men women respectively, 3.54 (0.82–15.39) DKA, 1.29 (1.13–1.48) depletion. Conclusions Among adults DKD, MACE, outcomes, HHF, death. With few exceptions more clear signals, we found overall limited data associations between outcomes. More research is needed profile this population.
Language: Английский
Citations
91
Cell Metabolism, Journal Year: 2024, Volume and Issue: 36(6), P. 1302 - 1319.e12
Published: June 1, 2024
Language: Английский
Citations
27
Frontiers in Endocrinology, Journal Year: 2021, Volume and Issue: 12
Published: May 20, 2021
Diabetes is a highly prevalent metabolic disease that has emerged as global challenge due to its increasing prevalence and lack of sustainable treatment. Diabetic kidney (DKD), which one the most frequent severe microvascular complications diabetes, difficult treat with contemporary glucose-lowering medications. The gut microbiota plays an important role in human health disease, metabolites have both beneficial harmful effects on vital physiological processes. In this review, we summarize current findings regarding microbial development progression DKD, will help us better understand possible mechanisms DKD explore potential therapeutic approaches for DKD.
Language: Английский
Citations
48
Kidney360, Journal Year: 2022, Volume and Issue: 3(3), P. 455 - 464
Published: Jan. 19, 2022
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic (CKD), regardless of diabetes status. However, the prescribing patterns these novel therapeutics CKD population real-world settings remain largely unknown.
Language: Английский
Citations
33
Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(11)
Published: June 1, 2024
Abstract Diabetic kidney disease (DKD) is a leading cause of end stage renal with unmet clinical demands for treatment. Lipids are essential cell survival; however, cells have limited capability to metabolize overloaded lipids. Dyslipidaemia common in DKD patients and ectopic lipid accumulation associated progression. Unveiling the molecular mechanism involved regulation crucial exploring potential therapeutic targets. In this review, we focused on underlying cholesterol, oxysterol fatty acid metabolism disorder context DKD. Specific regulators different compartment TREM2 macrophages, lipid‐related macrophages DKD, were discussed. The role sodium‐glucose transporter 2 inhibitors improving was summarized.
Language: Английский
Citations
7
Diabetes Metabolic Syndrome and Obesity, Journal Year: 2024, Volume and Issue: Volume 17, P. 943 - 957
Published: Feb. 1, 2024
This research aims to examine and scrutinize gender variations in the incidence of diabetic nephropathy (DN) trajectory renal function type 2 diabetes mellitus (T2DM) patients.
Language: Английский
Citations
6
Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(10), P. 3377 - 3377
Published: May 10, 2023
Chronic kidney disease (CKD) is associated with increased morbidity and mortality, especially from cardiovascular (CV) causes, in people diabetes mellitus (DM). Already the presence of DM increases CV risk potentiates CKD. Therefore, besides glycemic control, prevention treatment CKD to slow its progression are clinical importance. A significant nephroprotective effect novel antidiabetic drugs, namely sodium-glucose cotransporter 2 inhibitors (SGLT2-I) glucagon-like peptide 1 receptor agonists (GLP1-RA), has been shown on top their glucose-lowering effects was confirmed outcome trials. GLP1-RA mainly reduced macroalbuminuria, whereas SGLT2-I were also a lower declining glomerular filtration rate (GFR) over time. The evident without DM. According current guidelines, and/or recommended for who have chronic risk. However, other drugs offer properties, which will be discussed this review.
Language: Английский
Citations
16
Mayo Clinic Proceedings, Journal Year: 2022, Volume and Issue: 97(10), P. 1904 - 1919
Published: Oct. 1, 2022
Chronic kidney disease due to diabetes, or diabetic (DKD), is a worldwide leading cause of chronic and failure an increasingly important global public health issue. It associated with poor quality life, high burden diseases, increased risk premature death. Until recently, people DKD had limited therapeutic options. Treatments have focused largely on glycemic blood pressure control renin-angiotensin system blockade, leaving patients significant residual for progression DKD. The availability newer classes glucose-lowering agents, namely, sodium-glucose cotransporter 2 inhibitors glucagon-like peptide 1 receptor agonists, has changed the landscape these patients. These therapies offered unprecedented opportunities reduce death that led recent updates clinical guidelines. As such, American Diabetes Association, Kidney Disease: Improving Global Outcomes, European Association Study now recommend use agonists provide both cardiovascular protective benefits. This review highlights importance early detection summarizes latest recommendations in guidelines management hope facilitating their uptake into everyday practice. An integrated approach patient care multidisciplinary focus can help achieve necessary shift
Language: Английский
Citations
20
Cureus, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 20, 2025
Objective: This study aims to evaluate the effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin, on prevention heart failure hospitalizations improvement metabolic control in patients with type 2 diabetes mellitus (T2DM) without documented high cardiovascular risk. The aimed assess impact these treatments glycemic control, blood pressure, weight, outcomes over an 18-month follow-up period a Colombian population. Materials methods: A retrospective cohort was conducted 122 uncontrolled T2DM at Clínica Imbanaco Cali, Colombia. Five treatment groups were identified, including various metformin combinations other agents intensified dapagliflozin. Patients retrospectively followed for 18 months, assessing first hospitalization due failure, body weight. Multivariate repeated-measures ANOVA used analyze clinical variable changes time. Additionally, Kaplan-Meier survival analysis estimated cumulative probability each group, Cox regression evaluated associations between different risk hospitalization. Results: treated + showed significant reduction HbA1c levels, from initial mean 7.75% 6.77% end (-0.97%; 95% CI: -1.31 -0.63, p < 0.001) compared baseline. Blood pressure group also decreases. Final systolic reached average 120.40 mmHg (95% -22.63 1.54, > 0.05), reflecting -10.55 Diastolic decreased 78 -10.71 -0.69, -5.7 Regarding hospitalizations, indicated HR 0 (p 0.001), no reported during period. Conclusions: Analysis left ventricular ejection fraction inhibitors reveals that is not only effective weight management, but shows preventive potential against progression, even These findings, aligned evidence classical studies, suggest should be considered early management reduce incidence improve long-term outcomes.
Language: Английский
Citations
0